Company: SHPH
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001493152-25-008300
Chunk: 198

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 1A
Chunk 198
---
 event the Company has not regained compliance prior to the end of May 2025, the Company will
    have to effectuate a reverse stock split in order to regain compliance.

    ●
    On
    September 10, 2024, the Company received a letter from Nasdaq notifying the Company that it is no longer in compliance with the
    minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1)
    requires listed companies to maintain stockholders’ equity of at least $2,500,000. In the Company’s Quarterly Report
    on Form 10-Q for the period ended June 30, 2024, the Company reported stockholders’ equity of $801,434, which is below the
    minimum stockholders’ equity required for continued listing pursuant to Nasdaq Listing Rule 5550(b)(1). In addition, presently,
    the Company does not meet the alternatives of market value of listed securities or net income from continuing operations

    ●
    Our
    stock price may be volatile, and purchasers of our common stock could incur substantial losses.

    ●
    The
    future issuance of equity or of debt securities that are convertible into common stock will dilute our share capital.

    ●
    If
    securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading
    opinion regarding our stock, our stock price and trading volume could decline. 

    ●
    The
    restatement of our financial statements and identification of material weaknesses in our internal controls may result in additional
    risks and uncertainties, including regulatory, stockholder or other actions, loss of investor and counterparty confidence and negative
    impacts on our stock price.

    ●
    If
    we fail to comply with Nasdaq’s continued listing requirements, it could result in our common stock being delisted, which could
    adversely affect the market price and liquidity of our securities and could have other adverse effects. 

21

RISK
FACTORS

An
investment in our common stock involves a high degree of risk. You should carefully consider the following risk factors and all the other
information in this Annual Report before you decide to buy our common stock. If any of the following risks related to our business actually
occurs, our business, financial condition, operating results, and prospects would be adversely affected. The market price of our common
stock could decline due to